Doc logic.
Agreed that immune memory is the most important protection against recurrence and hope that most treatment patients received a sufficient number of vaccine doses.
However, Dr. Liau's recent April 2019 presentation has me worried again that a number of post chemorad treated placebo/control patients who then developed signs of psPD, were mistaken as having genuine progression and were consequently treated with DCVax-L. If that is true, I was wrong to believe that they had avoided this problem by being able to identify most if not all of these patients earlier in the trial. I can only hope that the number of such patients is minimal and will not change the basic outcome of this trial.
Finally what is INMD?
Best wishes